---
document_datetime: 2025-12-29 11:44:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mayzent.html
document_name: mayzent.html
version: success
processing_time: 0.1280071
conversion_datetime: 2025-12-29 23:19:19.274948
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mayzent

[RSS](/en/individual-human-medicine.xml/67272)

##### Authorised

This medicine is authorised for use in the European Union

siponimod Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mayzent](#news-on)
- [More information on Mayzent](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mayzent is a medicine used to treat adults with an advanced form of multiple sclerosis (MS) known as secondary progressive MS.

It is used in patients with active disease, which means that patients still have relapses or signs of inflammation can be seen in scans.

Mayzent contains the active substance siponimod.

Expand section

Collapse section

## How is Mayzent used?

Mayzent can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the management of MS.

Mayzent is available as tablets and should be taken once a day. Treatment is started with a dose of 0.25 mg daily for two days. The dose is then progressively increased to reach the 'maintenance' dose on the sixth day. The maintenance dose is either 1 mg or 2 mg daily, depending on how quickly the patient's body can process the medicine. This is determined by the use of a blood or saliva test to measure the activity of the patient's liver enzyme CYP2C9.

For more information about using Mayzent, see the package leaflet or contact your doctor or pharmacist.

## How does Mayzent work?

In MS, the immune system (the body's defences) attacks and damages the protective sheath around the nerves in the brain and spinal cord.

The active substance in Mayzent, siponimod, blocks the action of some receptors (targets) on cells called sphingosine-1-phosphate receptors, which are involved in the movement of lymphocytes (immune cells) around the body. By attaching to these receptors, siponimod stops lymphocytes from travelling from the lymph nodes towards the brain and spinal cord, thus limiting the damage they cause in MS.

## What benefits of Mayzent have been shown in studies?

Mayzent was shown to be effective at delaying the progression of the disease in a 3-year main study involving 1,651 patients with secondary progressive MS, of whom 779 had active disease with a relapse within 2 years or other signs of inflammation in scans.

Disease progression was defined as worsening of the disease that is independent from a relapse and is maintained over at least 3 months, as assessed using a standard scale called EDSS. During the study, 25% of patients with active secondary progressive MS taking Mayzent had disease progression compared with 35% of patients taking placebo (a dummy treatment).

## What are the risks associated with Mayzent?

The most common side effects with Mayzent (which may affect more than 1 in 10 people) are headache and hypertension (high blood pressure).

Mayzent must not be used in patients who are hypersensitive (allergic) to siponimod, or to peanut, soya or any of the other ingredients of the medicine. The medicine must also not be used in patients who previously had certain severe infections (known as progressive multifocal leukoencephalopathy or cryptococcal meningitis). Mayzent must also not be used in patients with cancer and certain immune disorders due to its effect on the immune system. It must not be used in patients who have recently had a stroke and in patients with certain heart disorders (because of its effects on heart rate and blood pressure), severe liver disorders and in pregnant women and women who can become pregnant and are not using effective contraception.

Mayzent must also not be used in patients who have inherited a gene known as CYP2C9*3 from both parents, which makes them unable to process the medicine fast enough. For the full list of side effects and restrictions of Mayzent, see the package leaflet.

## Why is Mayzent authorised in the EU?

Mayzent was effective at delaying the progression of secondary progressive MS in patients with active disease; however, the beneficial effects of the medicine were not demonstrated in patients without an active disease. The European Medicines Agency therefore decided that Mayzent should only be used in patients whose disease is active with signs of inflammation.

The side effects with Mayzent are similar to those with another medicine (fingolimod) for MS working in a similar way and are considered acceptable.

The Agency therefore decided that Mayzent's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mayzent?

The company that markets Mayzent will ensure that doctors expected to prescribe the medicine receive educational materials, including a checklist covering the necessary screening, pre-treatment and long-term monitoring of patients. The materials will include a guide for patients with key safety information about Mayzent, as well as a pregnancy reminder card for women who can become pregnant.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mayzent have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mayzent are continuously monitored. Side effects reported with Mayzent are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mayzent

Mayzent received a marketing authorisation valid throughout the EU on 13 January 2020.

Mayzent : EPAR - Medicine overview

Reference Number: EMA/629863/2019

English (EN) (120.12 KB - PDF)

**First published:** 23/01/2020

[View](/en/documents/overview/mayzent-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-460)

български (BG) (143.5 KB - PDF)

**First published:**

23/01/2020

[View](/bg/documents/overview/mayzent-epar-medicine-overview_bg.pdf)

español (ES) (119.22 KB - PDF)

**First published:**

23/01/2020

[View](/es/documents/overview/mayzent-epar-medicine-overview_es.pdf)

čeština (CS) (140.57 KB - PDF)

**First published:**

23/01/2020

[View](/cs/documents/overview/mayzent-epar-medicine-overview_cs.pdf)

dansk (DA) (117.93 KB - PDF)

**First published:**

23/01/2020

[View](/da/documents/overview/mayzent-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.97 KB - PDF)

**First published:**

23/01/2020

[View](/de/documents/overview/mayzent-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.12 KB - PDF)

**First published:**

23/01/2020

[View](/et/documents/overview/mayzent-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.75 KB - PDF)

**First published:**

23/01/2020

[View](/el/documents/overview/mayzent-epar-medicine-overview_el.pdf)

français (FR) (120.39 KB - PDF)

**First published:**

23/01/2020

[View](/fr/documents/overview/mayzent-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.95 KB - PDF)

**First published:**

23/01/2020

[View](/hr/documents/overview/mayzent-epar-medicine-overview_hr.pdf)

italiano (IT) (117.88 KB - PDF)

**First published:**

23/01/2020

[View](/it/documents/overview/mayzent-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.98 KB - PDF)

**First published:**

23/01/2020

[View](/lv/documents/overview/mayzent-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.77 KB - PDF)

**First published:**

23/01/2020

[View](/lt/documents/overview/mayzent-epar-medicine-overview_lt.pdf)

magyar (HU) (140.16 KB - PDF)

**First published:**

23/01/2020

[View](/hu/documents/overview/mayzent-epar-medicine-overview_hu.pdf)

Malti (MT) (142.91 KB - PDF)

**First published:**

23/01/2020

[View](/mt/documents/overview/mayzent-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.98 KB - PDF)

**First published:**

23/01/2020

[View](/nl/documents/overview/mayzent-epar-medicine-overview_nl.pdf)

polski (PL) (142.74 KB - PDF)

**First published:**

23/01/2020

[View](/pl/documents/overview/mayzent-epar-medicine-overview_pl.pdf)

português (PT) (119.84 KB - PDF)

**First published:**

23/01/2020

[View](/pt/documents/overview/mayzent-epar-medicine-overview_pt.pdf)

română (RO) (139.64 KB - PDF)

**First published:**

23/01/2020

[View](/ro/documents/overview/mayzent-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.71 KB - PDF)

**First published:**

23/01/2020

[View](/sk/documents/overview/mayzent-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.77 KB - PDF)

**First published:**

23/01/2020

[View](/sl/documents/overview/mayzent-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.37 KB - PDF)

**First published:**

23/01/2020

[View](/fi/documents/overview/mayzent-epar-medicine-overview_fi.pdf)

svenska (SV) (117.42 KB - PDF)

**First published:**

23/01/2020

[View](/sv/documents/overview/mayzent-epar-medicine-overview_sv.pdf)

Mayzent : EPAR - Risk management plan

English (EN) (3.21 MB - PDF)

**First published:** 23/01/2020

**Last updated:** 24/11/2025

[View](/en/documents/rmp/mayzent-epar-risk-management-plan_en.pdf)

## Product information

Mayzent : EPAR - Product information

English (EN) (945.3 KB - PDF)

**First published:** 23/01/2020

**Last updated:** 15/10/2025

[View](/en/documents/product-information/mayzent-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-478)

български (BG) (1.36 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/bg/documents/product-information/mayzent-epar-product-information_bg.pdf)

español (ES) (2.4 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/es/documents/product-information/mayzent-epar-product-information_es.pdf)

čeština (CS) (1.39 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/cs/documents/product-information/mayzent-epar-product-information_cs.pdf)

dansk (DA) (1.24 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/da/documents/product-information/mayzent-epar-product-information_da.pdf)

Deutsch (DE) (1.34 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/de/documents/product-information/mayzent-epar-product-information_de.pdf)

eesti keel (ET) (3.68 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/et/documents/product-information/mayzent-epar-product-information_et.pdf)

ελληνικά (EL) (1.44 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/el/documents/product-information/mayzent-epar-product-information_el.pdf)

français (FR) (2.93 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/fr/documents/product-information/mayzent-epar-product-information_fr.pdf)

hrvatski (HR) (2.72 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/hr/documents/product-information/mayzent-epar-product-information_hr.pdf)

íslenska (IS) (2.84 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/is/documents/product-information/mayzent-epar-product-information_is.pdf)

italiano (IT) (2.58 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/it/documents/product-information/mayzent-epar-product-information_it.pdf)

latviešu valoda (LV) (2.17 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/lv/documents/product-information/mayzent-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.19 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/lt/documents/product-information/mayzent-epar-product-information_lt.pdf)

magyar (HU) (2.44 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/hu/documents/product-information/mayzent-epar-product-information_hu.pdf)

Malti (MT) (2.93 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/mt/documents/product-information/mayzent-epar-product-information_mt.pdf)

Nederlands (NL) (2.43 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/nl/documents/product-information/mayzent-epar-product-information_nl.pdf)

norsk (NO) (2.46 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/no/documents/product-information/mayzent-epar-product-information_no.pdf)

polski (PL) (2.81 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/pl/documents/product-information/mayzent-epar-product-information_pl.pdf)

português (PT) (2.84 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/pt/documents/product-information/mayzent-epar-product-information_pt.pdf)

română (RO) (2.8 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/ro/documents/product-information/mayzent-epar-product-information_ro.pdf)

slovenčina (SK) (3.11 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/sk/documents/product-information/mayzent-epar-product-information_sk.pdf)

slovenščina (SL) (824.56 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/sl/documents/product-information/mayzent-epar-product-information_sl.pdf)

Suomi (FI) (2.22 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/fi/documents/product-information/mayzent-epar-product-information_fi.pdf)

svenska (SV) (2.11 MB - PDF)

**First published:**

23/01/2020

**Last updated:**

15/10/2025

[View](/sv/documents/product-information/mayzent-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000255116 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mayzent : EPAR - All authorised presentations

English (EN) (93.93 KB - PDF)

**First published:** 23/01/2020

**Last updated:** 18/02/2022

[View](/en/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-783)

български (BG) (103.15 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/bg/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_bg.pdf)

español (ES) (94.21 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/es/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_es.pdf)

čeština (CS) (97.96 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/cs/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (94.61 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/da/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (95.72 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/de/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (94.28 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/et/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (100.27 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/el/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_el.pdf)

français (FR) (94.87 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/fr/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (95.72 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/hr/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (96.09 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/is/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_is.pdf)

italiano (IT) (94.15 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/it/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (98.58 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/lv/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (99.18 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/lt/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (99.24 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/hu/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (98.84 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/mt/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (93.07 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/nl/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (94.94 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/no/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_no.pdf)

polski (PL) (98.96 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/pl/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_pl.pdf)

português (PT) (94.92 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/pt/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_pt.pdf)

română (RO) (96.75 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/ro/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (98.97 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/sk/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (92.97 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/sl/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (93.35 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/fi/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (94.64 KB - PDF)

**First published:**

23/01/2020

**Last updated:**

18/02/2022

[View](/sv/documents/all-authorised-presentations/mayzent-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mayzent Active substance siponimod fumaric acid International non-proprietary name (INN) or common name siponimod Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04

### Pharmacotherapeutic group

Selective immunosuppressants

### Therapeutic indication

Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

## Authorisation details

EMA product number EMEA/H/C/004712 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 14/11/2019 Marketing authorisation issued 13/01/2020 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mayzent : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.32 KB - PDF)

**First published:** 15/10/2025

[View](/en/documents/procedural-steps-after/mayzent-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

Mayzent : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (204.06 KB - PDF)

**First published:** 24/03/2020

**Last updated:** 06/05/2025

[View](/en/documents/procedural-steps-after/mayzent-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Mayzent-H-C-PSUSA-00010818-202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/512741/2024

English (EN) (130.74 KB - PDF)

**First published:** 17/01/2025

[View](/en/documents/scientific-conclusion/mayzent-h-c-psusa-00010818-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Mayzent-PSUSA-00010818-202303 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/484731/2023

English (EN) (149.91 KB - PDF)

**First published:** 08/01/2024

[View](/en/documents/scientific-conclusion/mayzent-psusa-00010818-202303-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mayzent-PSUSA-00010818-202203 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/856981/2022

English (EN) (126.55 KB - PDF)

**First published:** 31/01/2023

[View](/en/documents/scientific-conclusion/mayzent-psusa-00010818-202203-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mayzent-PSUSA-00010818-202109: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/260476/2022

English (EN) (145.93 KB - PDF)

**First published:** 25/07/2022

[View](/en/documents/scientific-conclusion/mayzent-psusa-00010818-202109-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mayzent-H-C-4712-X-07 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/11848/2022

English (EN) (544.79 KB - PDF)

**First published:** 18/02/2022

[View](/en/documents/variation-report/mayzent-h-c-4712-x-07-epar-assessment-report-variation_en.pdf)

Mayzent-PSUSA-00010818-202003: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/666450/2020

English (EN) (131.25 KB - PDF)

**First published:** 14/01/2021

[View](/en/documents/scientific-conclusion/mayzent-psusa-00010818-202003-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Mayzent : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/652767/2019

English (EN) (3.3 MB - PDF)

**First published:** 23/01/2020

[View](/en/documents/assessment-report/mayzent-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mayzent

Adopted

Reference Number: EMA/CHMP/596356/2019

English (EN) (67.99 KB - PDF)

**First published:** 15/11/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mayzent_en.pdf-0)

#### News on Mayzent

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated) 15/11/2019

#### More information on Mayzent

- [EMEA-000716-PIP01-09-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000716-pip01-09-m05)
- [Survey among healthcare professionals (neurologists treating patients with MS along with MS specialist nurses) and patients in selected European countries plus Canada to evaluate the knowledge required for the safe use of Mayzent (siponimod) - post-authorisation study](https://catalogues.ema.europa.eu/study/44783)
- [Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated with Mayzent (siponimod): An OTIS Observational Pregnancy Surveillance Study - post-authorisation study](https://catalogues.ema.europa.eu/study/43835)
- [Registro español de alteraciones hematoogicas durante el tratamiento con siponimod. (SILITOX Study) - post-authorisation study](https://catalogues.ema.europa.eu/study/45188)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/11/2025

## Share this page

[Back to top](#main-content)